drugset / Trial / NCT01881633

A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

NCT01881633

Phase 1 Completed 24 enrolled ISU Abxis Co., Ltd.
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single dosing study with three ascending dose cohorts of ISU302 in healthy subjects.

Timeline

Start
2010-10
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ISU302 Protein / enzyme biologic 15 iu/kg Intravenous
Subject ISU302 Protein / enzyme biologic 30 iu/kg Intravenous
Subject ISU302 Protein / enzyme biologic 60 iu/kg Intravenous

Indications